FDG-PET for detecting local tumor recurrence of ablated liver metastases: A diagnostic meta-analysis

Biomarkers

Volumn 17, Issue 6, 2012, Pages 532-538

  Poulou, Loukia S ^a   Ziakas, Panayiotis D ^b   Ziogas, Dimitrios C ^b   Doxani, Chrysoula ^c   Xyla, Vassilia ^b   Vakrinos, George ^a   Voulgarelis, Michael ^b   Thanos, Loukas ^a  

^a IASO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF THESSALY   (Greece)

Author keywords

Meta analysis; Metastasis; Positron emission tomography; Radiofrequency ablation

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; EMBASE; FOLLOW UP; HUMAN; LIVER INJURY; LIVER METASTASIS; MEDLINE; POSITRON EMISSION TOMOGRAPHY; RADIOFREQUENCY ABLATION; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

AREA UNDER CURVE; CATHETER ABLATION; COLORECTAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOSURGERY; ROC CURVE;

EID: 84865724181     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.699553     Document Type: Article

References (47)

1. Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galantowicz PJ, Carbone GM, Spaulding MB. (1998). Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings. Radiology 206:755-760.
2. Anderson GS, Brinkmann F, Soulen MC, Alavi A, Zhuang H. (2003). FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 28:192-197.
3. Antoch G, Vogt FM, Veit P, Freudenberg LS, Blechschmid N, Dirsch O, Bockisch A, Forsting M, Debatin JF, Kuehl H. (2005). Assessment of liver tissue after radiofrequency ablation: Findings with different imaging procedures. J Nucl Med 46:520-525.
4. Ayav A, Germain A, Marchal F, Tierris I, Laurent V, Bazin C, Yuan Y, Robert L, Brunaud L, Bresler L. (2010). Radiofrequency ablation of unresectable liver tumors: Factors associated with incomplete ablation or local recurrence. Am J Surg 200:435-439.
5. Battaglia M, Bucher H, Egger M, Grossenbacher F, Minder C, and Pewsner D. (2002). The Bayes library of diagnostic studies and reviews, 2nd edition, Basel, Switzerland: University of Basel.
6. Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, Stoker J. (2005). Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 237:123-131.
7. Blokhuis TJ, van der Schaaf MC, van den Tol MP, Comans EF, Manoliu RA, van der Sijp Jr. (2004). Results of radio frequency ablation of primary and secondary liver tumors: Long-term follow-up with computed tomography and positron emission tomography- 18F-deoxyfluoroglucose scanning. Scand J Gastroenterol Suppl:93-:97.
8. Curley SA. (2001). Radiofrequency ablation of malignant liver tumors. Oncologist 6:14-23.
9. Delbeke D, Vitola JV, Sandler MP, Arildsen RC, Powers TA, Wright JK Jr, Chapman WC, Pinson CW. (1997). Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 38:1196-1201.
10. Donckier V, Van Laethem JL, Goldman S, Van Gansbeke D, Feron P, Ickx B, Wikler D, Gelin M. (2003). [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol 84:215-223.
11. Dromain C, de Baere T, Elias D, Kuoch V, Ducreux M, Boige V, Petrow P, Roche A, Sigal R. (2002). Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology 223:255-262.
12. Eisele RM, Neumann U, Neuhaus P, Schumacher G. (2009). Open surgical is superior to percutaneous access for radiofrequency ablation of hepatic metastases. World J Surg 33:804-811.
13. Irwig L, Tosteson AN, Gatsonis C, Lau J, Colditz G, Chalmers TC, Mosteller F. (1994). Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med 120:667-676.
14. Irwig L, Macaskill P, Glasziou P, Fahey M. (1995). Meta-analytic methods for diagnostic test accuracy. J Clin Epidemiol 48:119-30; discussion 131.
15. Khandani AH, Calvo BF, O'Neil BH, Jorgenson J, Mauro MA. (2007). A pilot study of early 18F-FDG PET to evaluate the effectiveness of radiofrequency ablation of liver metastases. AJR Am J Roentgenol 189:1199-1202.
16. Kuehl H, Antoch G, Stergar H, Veit-Haibach P, Rosenbaum-Krumme S, Vogt F, Frilling A, Barkhausen J, Bockisch A. (2008). Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: Initial results. Eur J Radiol 67:362-371.
17. Kuvshinoff BW, Ota DM. (2002). Radiofrequency ablation of liver tumors: Influence of technique and tumor size. Surgery 132:605- 11; discussion 611.
18. Langenhoff BS, Oyen WJ, Jager GJ, Strijk SP, Wobbes T, Corstens FH, Ruers TJ. (2002). Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: A prospective study. J Clin Oncol 20:4453-4458.
19. Lencioni R, Cioni D, Bartolozzi C. (2001). Percutaneous radiofrequency thermal ablation of liver malignancies: Techniques, indications, imaging findings, and clinical results. Abdom Imaging 26:345-360.
20. Lim HK, Choi D, Lee WJ, Kim SH, Lee SJ, Jang HJ, Lee JH, Lim JH, Choo IW. (2001). Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology 221:447-454.
21. Liu ZY, Chang ZH, Lu ZM, Guo QY. (2010). Early PET/CT after radiofrequency ablation in colorectal cancer liver metastases: Is it useful? Chin Med J 123:1690-1694.
22. Lubezky N, Metser U, Geva R, Nakache R, Shmueli E, Klausner JM, Even- Sapir E, Figer A, Ben-Haim M. (2007). The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: Comparison with operative and pathological findings. J Gastrointest Surg 11:472-478.
23. McGhana JP, Dodd GD 3rd. (2001). Radiofrequency ablation of the liver: Current status. AJR Am J Roentgenol 176:3-16.
24. Meta J, Seltzer M, Schiepers C, Silverman DH, Ariannejad M, Gambhir SS, Phelps ME, Valk P, Czernin J. (2001). Impact of 18F-FDG PET on managing patients with colorectal cancer: The referring physician's perspective. J Nucl Med 42:586-590.
25. Moses LE, Shapiro D, Littenberg B. (1993). Combining independent studies of a diagnostic test into a summary ROC curve: Data-analytic approaches and some additional considerations. Stat Med 12:1293-1316.
26. Owens DK, Holodniy M, Garber AM, Scott J, Sonnad S, Moses L, Kinosian B, Schwartz JS. (1996). Polymerase chain reaction for the diagnosis of HIV infection in adults. A meta-analysis with recommendations for clinical practice and study design. Ann Intern Med 124:803-815.
27. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. (2005). Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 58:982-990.
28. Rossi S, Di Stasi M, Buscarini E, Quaretti P, Garbagnati F, Squassante L, Paties CT, Silverman DE, Buscarini L. (1996). Percutaneous RF 538 L. S. Poulou et al. Biomarkers interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol 167:759-768.
29. Rossi S, Buscarini E, Garbagnati F, Di Stasi M, Quaretti P, Rago M, Zangrandi A, Andreola S, Silverman D, Buscarini L. (1998). Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR Am J Roentgenol 170:1015-1022.
30. Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, Corstens FH, Oyen WJ. (2002). Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: A prospective study. J Clin Oncol 20:388-395.
31. Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. (2011a). Value of PET/CT in the management of liver metastases, part 1. AJR Am J Roentgenol 197:W256-W259.
32. Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. (2011b). Value of PET/CT in the management of primary hepatobiliary tumors, part 2. AJR Am J Roentgenol 197:W260-W265.
33. Sahin DA, Agcaoglu O, Chretien C, Siperstein A, Berber E. (2012). The utility of PET/CT in the management of patients with colorectal liver metastases undergoing laparascopic radiofrequency thermal ablation. Ann Surg Oncol 19:850-855.
34. Schima W, Kulinna C, Langenberger H, Ba-Ssalamah A. (2005). Liver metastases of colorectal cancer: US, CT or MR? Cancer Imaging 5 Spec No A:S149-S156.
35. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. (2004). Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 240:1027-34; discussion 1035.
36. Solbiati L, Ierace T, Tonolini M, Osti V, Cova L. (2001). Radiofrequency thermal ablation of hepatic metastases. Eur J Ultrasound 13:149-158.
37. Sotiriadis A, Makrydimas G, Ioannidis JP. (2003). Diagnostic performance of intracardiac echogenic foci for Down syndrome: A meta-analysis. Obstet Gynecol 101:1009-1016.
38. Thanos L, Mylona S, Galani P, Pomoni M, Pomoni A, Koskinas I. (2008). Overcoming the heat-sink phenomenon: Successful radiofrequency thermal ablation of liver tumors in contact with blood vessels. Diagn Interv Radiol 14:51-56.
39. Travaini LL, Trifiro G, Ravasi L, Monfardini L, Della Vigna P, Bonomo G, Chiappa A, Mallia A, Ferrari M, Orsi F, Paganelli G. (2008). Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results. Eur J Nucl Med Mol Imaging 35:1316-1322.
40. Tsuda M, Rikimaru H, Majima K, Yamada T, Saito H, Ishibashi T, Takahashi S, Miyachi H, Endoh M, Yamada S. (2003). Time-related changes of radiofrequency ablation lesion in the normal rabbit liver: Findings of magnetic resonance imaging and histopathology. Invest Radiol 38:525-531.
41. Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H. (2006). Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: Initial results. Eur Radiol 16:80-87.
42. Vogt FM, Antoch G, Veit P, Freudenberg LS, Blechschmid N, Diersch O, Bockisch A, Barkhausen J, Kuehl H. (2007). Morphologic and functional changes in nontumorous liver tissue after radiofrequency ablation in an in vivo model: Comparison of 18FFDG PET/CT, MRI, ultrasound, and CT. J Nucl Med 48:1836-1844.
43. Walter SD. (2002). Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 21:1237-1256.
44. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM; QUADAS-2 Group. (2011). QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529-536.
45. Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD 3rd, Dorfman GS, Eng C, Fong Y, Giusti AF, Lu D, Marsland TA, Michelson R, Poston GJ, Schrag D, Seidenfeld J, Benson AB 3rd. (2010). American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28:493-508.
46. Ziakas PD, Poulou LS, Voulgarelis M, Thanos L. (2012). The Gordian knot of interim 18-fluorodeoxyglucose positron emission tomography for Hodgkin lymphoma: A meta-analysis and commentary on published studies. Leuk Lymphoma, May 22 [Epub ahead of print].
47. Zintzaras E, Germenis AE. (2006). Performance of antibodies against tissue transglutaminase for the diagnosis of celiac disease: metaanalysis. Clin Vaccine Immunol 13:187-192.